Indian Army Department Of Military Affairs Medical Supplies Tender 2025 for Injections and Anesthetics - IS 550/ISI Compliance 2025

Tender Overview

The Indian Army, Department Of Military Affairs, seeks procurement of injectable pharmaceutical products including Ondansertron 2mg/4ml, Heparin 5000 IU/ml, Tranexamic acid 500mg/5ml, Adenosine 3mg/ml (2 ml), Amiodarone HCL 150mg/3ml, Esmolol 100mg/10ml, Labetalol HCL 5mg/ml/4ml, Hyoscine bromide 20mg/ml, Atracurium 10mg/ml (2.5 ml), Glycopyrrolate 0.2 mg/ml, Neostigmine 0.5 mg/ml, Succinylcholine chloride 50mg/ml, Vecuronium bromide 4mg/ml, across 13 items. Estimated value and EMD are not disclosed. Location unspecified; procurement focuses on critical injectable drugs for military medical readiness. A minimum shelf-life clause and pre/post-dispatch inspection options shape quality control requirements. Distinctive terms include option quantity adjustments up to 50% and a strong emphasis on brand/manufacturer disclosure and BOQ compliance. This tender is positioned as a high-priority government medical supply opportunity with compulsory drug-licensing and performance documentation.

• Organization: Indian Army (Department Of Military Affairs)
• Product/Service: Injectable pharmaceuticals and anesthetic agents
• Location: India (country-wide procurement context; location not specified)
• Quantity/Value: 13 items; exact quantities and estimated value not provided
• Key differentiator: Shelf-life minimum 80% at supply; option clause allowing up to 50% quantity variance; mandatory BOQ compliance and brand/manufacturer disclosure

Technical Specifications & Requirements

• Product category includes a range of injectable drugs with precise concentrations (e.g., Ondansertron 2mg/4ml, Heparin 5000 IU/ml, Tranexamic acid 500mg/5ml, Adenosine 3mg/ml, Amiodarone HCL 150mg/3ml, Esmolol 100mg/10ml, Labetalol HCL 5mg/ml/4ml, Hyoscine bromide 20mg/ml, Atracurium 10mg/ml (2.5 ml), Glycopyrrolate 0.2 mg/ml, Neostigmine 0.5 mg/ml, Succinylcholine 50mg/ml, Vecuronium bromide 4mg/ml).
• Shelf life requirement: minimum 80% usable shelf life on date of supply
• Inspection: Pre-dispatch or Post Receipt Inspection through nominated agency (BOO) as applicable
• Documentation: must include valid drug license, past performance certificate or contract, seller turnover certificate, BOQ compliance sheet, and seller brand/manufacturer information
• Brand/manufacturer disclosure: mandatory for bidder submission; OEM authorization likely required
• Compliance and standards: explicit IS/ISO references not stated; emphasis on brand/manufacturer and BOQ alignment with specifications
• Delivery/inspection sequencing: inspection timing tied to pre/post-dispatch options; delivery timelines tied to contract terms and option clause
• Tender structure: 13 items in BOQ; item-specific quantities not disclosed

Terms, Conditions & Eligibility

• EMD: not disclosed in the terms; ensure supply reliability and compliance with agency expectations
• Documents required: PAN card, GSTIN, cancelled cheque, EFT mandate (bank-certified)
• Option clause: quantity can increase/decrease up to 50% at contract, with corresponding delivery timeline adjustments
• Shelf-life: minimum 80% at supply; usable shelf life balance required
• Inspection: Nominated Inspection Agency for pre-dispatch or post-receipt inspection
• Additional ATC: valid drug license, past performance, turnover certificate, BOQ compliance, and brand/manufacturer disclosure
• Delivery terms: extended delivery periods possible under option clause with calculated timelines
• Payment terms: not specified; bidders should anticipate standard government terms and documentation